uniQure N.V. (QURE)

Market Cap	1.36B +89.5%
Revenue (ttm)	18.09M -10.4%
Net Income	-208.87M
EPS	-3.49
Shares Out	63.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	702,471
Open	20.97
Previous Close	21.16
Day's Range	20.50 - 21.86
52-Week Range	8.73 - 71.50
Beta	0.87
Analysts	Buy
Price Target	45.50 (+110.55%)
Earnings Date	May 5, 2026

About QURE

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2007
• Employees: 221
• Stock Exchange: NASDAQ
• Ticker Symbol: QURE
• Website: https://www.uniqure.com

Financial Performance

In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.

Analyst Summary

According to 14 analysts, the average rating for QURE stock is "Buy." The 12-month stock price target is $45.5, which is an increase of 110.55% from the latest price.

Price Target

$45.5

(110.55% upside)

Analyst Consensus: Buy